Share-based Payment Arrangement, Expense of Allogene Therapeutics, Inc. from 30 Jun 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Allogene Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2018 to 30 Sep 2025.
  • Allogene Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,652,000, a 35% decline year-over-year.
  • Allogene Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $42,385,000, a 22% decline year-over-year.
  • Allogene Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $51,743,000, a 22% decline from 2023.
  • Allogene Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $65,951,000, a 21% decline from 2022.
  • Allogene Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $83,600,000, a 3.5% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Allogene Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $42,385,000 $8,652,000 -$4,735,000 -35% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $47,120,000 $8,685,000 -$4,874,000 -36% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $51,994,000 $12,175,000 +$251,000 +2.1% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $51,743,000 $12,873,000 -$2,278,000 -15% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $54,021,000 $13,387,000 -$2,013,000 -13% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $56,034,000 $13,559,000 -$3,041,000 -18% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $59,075,000 $11,924,000 -$6,876,000 -37% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $65,951,000 $15,151,000 -$2,095,000 -12% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $68,046,000 $15,400,000 -$5,748,000 -27% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $73,794,000 $16,600,000 -$6,291,000 -27% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $80,085,000 $18,800,000 -$3,515,000 -16% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $83,600,000 $17,246,000 -$4,772,000 -22% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $88,372,000 $21,148,000 +$292,000 +1.4% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $88,080,000 $22,891,000 +$1,757,000 +8.3% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $86,323,000 $22,315,000 +$5,523,000 +33% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $80,800,000 $22,018,000 +$5,526,000 +34% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q3 2021 $75,274,000 $20,856,000 +$3,033,000 +17% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $72,241,000 $21,134,000 +$4,364,000 +26% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $67,877,000 $16,792,000 +$2,577,000 +18% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $65,300,000 $16,492,000 +$2,617,000 +19% 01 Oct 2020 31 Dec 2020 10-K/A 14 Mar 2024 2022 FY
Q3 2020 $62,683,000 $17,823,000 +$4,989,000 +39% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $57,694,000 $16,770,000 +$5,283,000 +46% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $52,411,000 $14,215,000 +$6,348,000 +81% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $46,063,000 $13,875,000 01 Oct 2019 31 Dec 2019 10-K 23 Feb 2022 2021 FY
Q3 2019 $12,834,000 +$8,195,000 +177% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $11,487,000 +$3,431,000 +43% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $7,867,000 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q3 2018 $4,639,000 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $8,056,000 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2

Allogene Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $51,743,000 -$14,208,000 -22% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $65,951,000 -$17,649,000 -21% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $83,600,000 +$2,800,000 +3.5% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $80,800,000 +$15,500,000 +24% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
2020 $65,300,000 +$19,237,000 +42% 01 Jan 2020 31 Dec 2020 10-K/A 14 Mar 2024 2022 FY
2019 $46,063,000 +$27,497,000 +148% 01 Jan 2019 31 Dec 2019 10-K 23 Feb 2022 2021 FY
2018 $18,566,000 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.